➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Moodys
Baxter
Merck
Express Scripts

Last Updated: May 9, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AMIFAMPRIDINE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Amifampridine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01377922 A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) Completed Catalyst Pharmaceuticals, Inc. Phase 3 2011-06-01 A Phase 3 study to evaluate the efficacy and safety of Amifampridine Phosphate in patients with Lambert-Eaton Myasthenic Syndrome (LEMS).
NCT02189720 Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS), or Downbeat Nystagmus Patients Available Catalyst Pharmaceuticals, Inc. N/A 1969-12-31 The primary objective of the study is: • To provide patients with LEMS/CMS/downbeat nystagmus access to amifampridine phosphate therapy until the product becomes commercially available. The secondary objective of the study is: • To assess the long-term safety of amifampridine phosphate in patients with LEMS/CMS/downbeat nystagmus
NCT02562066 Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes Recruiting Catalyst Pharmaceuticals, Inc. Phase 3 2016-01-01 This randomized, double-blind, controlled, outpatient two-period, two-treatment crossover study is designed to evaluate the efficacy and safety of amifampridine phosphate in patients (ages 2 and above) diagnosed with certain genetic subtypes of CMS and demonstrated open label (amifampridine phosphate) or history of sustained amifampridine benefit from treatment.
NCT02970162 Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) Enrolling by invitation Catalyst Pharmaceuticals, Inc. Phase 3 2016-11-01 This study evaluates the effect of withdrawing amifampridine phosphate treatment from patients with LEMS. One half of the patients will continue to receive amifampridine phosphate and the other half will receive placebo, during this double-blind study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Amifampridine

Condition Name

Condition Name for Amifampridine
Intervention Trials
Lambert-Eaton Myasthenic Syndrome 2
Downbeat Nystagmus 1
Myasthenia Gravis, MuSK 1
Congenital Myasthenic Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Amifampridine
Intervention Trials
Syndrome 4
Lambert-Eaton Myasthenic Syndrome 4
Myasthenic Syndromes, Congenital 2
Muscular Atrophy, Spinal 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Amifampridine

Trials by Country

Trials by Country for Amifampridine
Location Trials
United States 21
Germany 2
Italy 1
Russian Federation 1
France 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Amifampridine
Location Trials
California 4
Ohio 2
Kansas 2
Texas 1
Tennessee 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Amifampridine

Clinical Trial Phase

Clinical Trial Phase for Amifampridine
Clinical Trial Phase Trials
Phase 3 5
Phase 2 2
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Amifampridine
Clinical Trial Phase Trials
Enrolling by invitation 2
Not yet recruiting 2
Recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Amifampridine

Sponsor Name

Sponsor Name for Amifampridine
Sponsor Trials
Catalyst Pharmaceuticals, Inc. 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Amifampridine
Sponsor Trials
Industry 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
AstraZeneca
McKinsey
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.